Hepatitis E virus infections can be life threatening and transmitted through blood products

April 12, 2018, European Association for the Study of the Liver

Hepatitis E virus (HEV) infection is once again in the spotlight, with two studies presented today at The International Liver Congress 2018 in Paris, France challenging the ideas that HEV infections are benign and self-limiting, and that blood-borne transmission is a rare event. Researchers from Hamburg and Hannover in Germany collaborating on these studies have demonstrated that HEV infections can be fatal in immunocompromised, and in some cases, immune-competent individuals. They also demonstrated that blood products are an important source of infection in those who are immunosuppressed.

Hepatitis E virus is one of the leading causes of acute viral hepatitis worldwide, with two main genotypes (genotypes 1 and 3) affecting humans.10 Genotype 1 predominates in low-income countries and is transmitted via the faecal-oral route, while genotype 3 predominates in high-income countries and has been linked to the consumption of contaminated pork or shellfish products.8 The reported incidence of HEV infection has been increasing steadily across Europe, with more than 21,000 cases reported in a recently evaluated decade (2005-2015).

In a large observational study presented this week in Paris, 150 HEV RNA-positive individuals were identified retrospectively from the records of two tertiary referral hospitals and transplant centres in Northern Germany. Of the 69 immune-competent individuals identified, 37 (53%) were hospitalized for a total of 74 days, and two of these individuals who had preexisting liver disease died after developing acute-on-chronic liver failure. Eight (10%) immunosuppressed patients died within 5 years of being diagnosed with HEV infection, with three of these deaths considered to be related to the HEV infection.

"We have shown in this study that HEV infection can be associated with significant morbidity and mortality, and that a severe disease course is not limited to those who are immunocompromised," said Dr. Sven Pischke from the University Hospital Hamburg-Eppendorf in Germany. "Based on these findings, we urge all hepatologists to consider HEV as a differential diagnosis in any patient who presents with acute-on-chronic liver failure."The second study involved a retrospective analysis of data from 37 immunosuppressed patients with HEV infection. Eleven of these patients (30%) developed chronic HEV infection and, in four of these individuals (36%), the source of infection could be traced to an HEV-positive blood donation. Two of these patients were heart transplant recipients who had been treated with a combination of plasmapheresis and rituximab for humoral rejection.

"The number of notified transfusion-transmitted HEV infections has so far been relatively low, probably due to under-reporting and under-recognition," said Dr. Dirk Westhölter from the University Hospital Hamburg-Eppendorf, who presented the study findings today. "This study confirms that blood products are an important source of HEV infection for immunosuppressed and it has led us to recommend HEV RNA screening of all blood products destined for transplant or immunosuppressed patients."

"Both studies emphasize the severity of hepatitis E virus infection in vulnerable patients," said Prof. Markus Cornberg from the Hannover Medical School, Germany, and EASL Governing Board Member. "Acute infection needs to be prevented by all measures in patients with advanced liver disease, and in immunocompromised . Blood products can be an important source of transmission. These studies will lead to further discussions around if and how HEV screening of products should be carried out."

Explore further: Blood donor screening for hepatitis E reveals incidence is higher than previously reported

Related Stories

Blood donor screening for hepatitis E reveals incidence is higher than previously reported

April 21, 2017
Results from a study presented today found that the incidence of HEV RNA in asymptomatic blood donors from Germany is higher than previously reported. The study, presented at The International Liver Congress 2017 in Amsterdam, ...

Punjab, India: Mass treatment of a population with chronic hepatitis C infection produces high rates of cure

April 12, 2018
A large-scale study evaluating the feasibility of decentralized care and the provision of free direct-acting antiviral agents (DAAs) has reported high rates of cure among a population of almost 20,000 individuals completing ...

Alcoholic liver disease replaces hepatitis C infection as the leading cause of liver transplantation

April 11, 2018
Two independent studies have today reported that alcoholic liver disease has now replaced hepatitis C virus (HCV) infection as the leading cause of liver transplantation in the USA in patients without HCC. Non-alcoholic steatohepatitis ...

Italy: Ongoing hepatitis A virus outbreak among men who have sex with men is linked to current outbreaks in Europe

April 12, 2018
Hepatitis A viruses (HAVs) circulating in an ongoing outbreak among men who have sex with men (MSM) in the Lombardy region of Italy are predominantly attributable to strains linked to two other recent outbreaks in Europe, ...

First real-world studies report glecaprevir/pibrentasvir to be effective and well tolerated in chronic HCV infection

April 12, 2018
The results of the first real-world studies assessing the effectiveness and safety of glecaprevir/pibrentasvir (G/P) in patients with chronic hepatitis C virus (HCV) infection have confirmed high rates of viral suppression ...

A third of bacterial infections in patients with cirrhosis across the world are multi-drug resistant

April 12, 2018
A worldwide study initiated to investigate the epidemiology and outcomes of bacterial infections in hospitalized patients with liver cirrhosis has reported a prevalence of multi-drug-resistant (MDR) bacteria of 34% and significant ...

Recommended for you

Drug targets for Ebola, Dengue, and Zika viruses found in lab study

December 13, 2018
No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes ...

Faster test for Ebola shows promising results in field trials

December 13, 2018
A team of researchers with members from the U.S., Senegal and Guinea, in cooperation with Becton, Dickinson and Company (BD), has developed a faster test for the Ebola virus than those currently in use. In their paper published ...

Urbanisation and air travel leading to growing risk of pandemic

December 13, 2018
Increased arrivals by air and urbanisation are the two main factors leading to a growing vulnerability to pandemics in our cities, a University of Sydney research team has found.

Researchers discover new interactions between Ebola virus and human proteins

December 13, 2018
Several new connections have been discovered between the proteins of the Ebola virus and human host cells, a finding that provides insight on ways to prevent the deadly Ebola virus from reproducing and could lead to novel ...

Faecal transplants, 'robotic guts' and the fight against deadly gut bugs

December 13, 2018
A simple compound found in our gut could help to stop dangerous bacteria behind severe, and sometimes fatal, hospital infections.

Taking the virus out of a mosquito's bite

December 12, 2018
They approach with the telltale sign—a high-pitched whine. It's a warning that you are a mosquito's next meal. But that mosquito might carry a virus, and now the virus is in you. Now, with the help of state-of-the-art technology, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.